Refinement of an ovine-based immunoglobulin therapy against SARS-CoV-2, with comparison of whole IgG versus F(ab')2 fragments
© 2023. Springer Nature Limited..
The development of new therapies against SARS-CoV-2 is required to extend the toolkit of intervention strategies to combat the global pandemic. In this study, hyperimmune plasma from sheep immunised with whole spike SARS-CoV-2 recombinant protein has been used to generate candidate products. In addition to purified IgG, we have refined candidate therapies by removing non-specific IgG via affinity binding along with fragmentation to eliminate the Fc region to create F(ab')2 fragments. These preparations were evaluated for in vitro activity and demonstrated to be strongly neutralising against a range of SARS-CoV-2 strains, including Omicron B2.2. In addition, their protection against disease manifestations and viral loads were assessed using a hamster SARS-CoV-2 infection model. Results demonstrated protective effects of both IgG and F(ab')2, with the latter requiring sequential dosing to maintain in vivo activity due to rapid clearance from the circulation.
| Errataetall: |
ErratumIn: Sci Rep. 2023 Sep 18;13(1):15419. - PMID 37723274 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Scientific reports - 13(2023), 1 vom: 25. Aug., Seite 13912 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Findlay-Wilson, Stephen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Immunoglobulin G |
|---|
| Anmerkungen: |
Date Completed 28.08.2023 Date Revised 06.03.2024 published: Electronic ErratumIn: Sci Rep. 2023 Sep 18;13(1):15419. - PMID 37723274 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-023-40277-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361242778 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361242778 | ||
| 003 | DE-627 | ||
| 005 | 20240306232359.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-023-40277-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM361242778 | ||
| 035 | |a (NLM)37626085 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Findlay-Wilson, Stephen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Refinement of an ovine-based immunoglobulin therapy against SARS-CoV-2, with comparison of whole IgG versus F(ab')2 fragments |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.08.2023 | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ErratumIn: Sci Rep. 2023 Sep 18;13(1):15419. - PMID 37723274 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. Springer Nature Limited. | ||
| 520 | |a The development of new therapies against SARS-CoV-2 is required to extend the toolkit of intervention strategies to combat the global pandemic. In this study, hyperimmune plasma from sheep immunised with whole spike SARS-CoV-2 recombinant protein has been used to generate candidate products. In addition to purified IgG, we have refined candidate therapies by removing non-specific IgG via affinity binding along with fragmentation to eliminate the Fc region to create F(ab')2 fragments. These preparations were evaluated for in vitro activity and demonstrated to be strongly neutralising against a range of SARS-CoV-2 strains, including Omicron B2.2. In addition, their protection against disease manifestations and viral loads were assessed using a hamster SARS-CoV-2 infection model. Results demonstrated protective effects of both IgG and F(ab')2, with the latter requiring sequential dosing to maintain in vivo activity due to rapid clearance from the circulation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Easterbrook, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Pope, Neville |e verfasserin |4 aut | |
| 700 | 1 | |a Aldridge, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Humphries, Gareth |e verfasserin |4 aut | |
| 700 | 1 | |a Schuhmann, Holger |e verfasserin |4 aut | |
| 700 | 1 | |a Ngabo, Didier |e verfasserin |4 aut | |
| 700 | 1 | |a Rayner, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Otter, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Coleman, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Hicks, Bethany |e verfasserin |4 aut | |
| 700 | 1 | |a Halkerston, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Apostolakis, Kostis |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Fotheringham, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Horton, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a CanoCejas, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Wand, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Tree, Julia A |e verfasserin |4 aut | |
| 700 | 1 | |a Sutton, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Graham, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Hewson, Roger |e verfasserin |4 aut | |
| 700 | 1 | |a Dowall, Stuart |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 13(2023), 1 vom: 25. Aug., Seite 13912 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:1 |g day:25 |g month:08 |g pages:13912 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-023-40277-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 1 |b 25 |c 08 |h 13912 | ||